Distribution and Associations of [-2]Proenzyme-Prostate Specific Antigen in Community Dwelling Black and White Men

Journal of Urology

Volumn 187, Issue 1, 2012, Pages 92-96

  Rhodes, Thomas ^a   Jacobson, Debra J ^b   McGree, Michaela E ^b   St Sauver, Jennifer L ^b   Sarma, Aruna V ^c   Girman, Cynthia J ^d   Lieber, Michael M ^b   Klee, George G ^b   Demissie, Kitaw ^a   Jacobsen, Steven J ^e  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Kaiser Permanente Southern California ^*  (United States)

Author keywords

enzyme precursors; prostate; prostate specific antigen; prostatic hyperplasia; prostatic neoplasms

Indexed keywords

ENZYME PRECURSOR; PROENZYME PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE DIFFERENCE;

AFRICAN AMERICANS; CROSS-SECTIONAL STUDIES; ENZYME PRECURSORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RESIDENCE CHARACTERISTICS;

EID: 83555162514     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.09.060     Document Type: Article

References (24)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. J.E. Oesterling, S.J. Jacobsen, and C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men Establishment of age-specific reference ranges JAMA 270 1993 860
3. W.J. Catalona, P.C. Southwick, and K.M. Slawin Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 56 2000 255
4. S.D. Mikolajczyk, L.S. Millar, and T.J. Wang A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue Cancer Res 60 2000 756
5. S.D. Mikolajczyk, W.J. Catalona, and C.L. Evans Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 2004 1017
6. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 2003 2181
7. T.Y. Chan, S.D. Mikolajczyk, and K. Lecksell Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen Urology 62 2003 177
8. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen J Urol 171 2004 2239
9. L.J. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193
10. C. Stephan, A.M. Kahrs, and H. Cammann A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases Prostate 69 2009 198
11. D.V. Makarov, S. Isharwal, and L.J. Sokoll Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer Clin Cancer Res 15 2009 7316
12. B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355
13. H.A. Guess, S.J. Jacobsen, and C.J. Girman The role of community-based longitudinal studies in evaluating treatment effects Example: benign prostatic hyperplasia Med Care 33 1995 AS26
14. S.J. Jacobsen, E.J. Bergstralh, and H.A. Guess Predictive properties of serum-prostate-specific antigen testing in a community-based setting Arch Intern Med 156 1996 2462
15. C.G. Chute, L.A. Panser, and C.J. Girman The prevalence of prostatism: a population-based survey of urinary symptoms J Urol 150 1993 85
16. J.T. Wei, D. Schottenfeld, and K. Cooper The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness J Urol 165 2001 1521
17. S.J. Jacobsen, H.A. Guess, and L. Panser A population-based study of health care-seeking behavior for treatment of urinary symptoms The Olmsted County Study of Urinary Symptoms and Health Status Among Men Arch Fam Med 2 1993 729
18. A.V. Sarma, J.T. Wei, and D.J. Jacobson Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study Urology 61 2003 1086
19. T. Rhodes, C.J. Girman, and S.J. Jacobsen Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old J Urol 161 1999 1174
20. M.K. Terris, and T.A. Stamey Determination of prostate volume by transrectal ultrasound J Urol 145 1991 984
21. S.J. Jacobsen, G.G. Klee, and H. Lilja Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time Urology 45 1995 447
22. J.E. Oesterling, M.A. Moyad, and G.L. Wright Jr An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx Urology 46 1995 524
23. S.H. de Vries, R. Raaijmakers, and B.G. Blijenberg Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer Urology 65 2005 926
24. A. Semjonow, T. Kopke, and E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 43 2010 926